stella
beta
A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants — Stella
Recruiting
Back to Transfusion-dependent α-Thalassemia trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
China
The affiliated hospital of guangxi medical university, Nanning, Guangxi
View full record on ClinicalTrials.gov